Unknown

Dataset Information

0

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.


ABSTRACT: Objective: A recent double-blind randomized placebo-controlled study demonstrated 3-month efficacy and safety of a novel pediatric-appropriate prolonged-release melatonin (PedPRM) for insomnia in children and adolescents with autism spectrum disorder (ASD) and neurogenetic disorders (NGD) with/without attention-deficit/hyperactivity disorder comorbidity. Long-term efficacy and safety of PedPRM treatment was studied. Methods: A prospective, open-label efficacy and safety follow-up of nightly 2, 5, or 10?mg PedPRM in subjects who completed the 13-week double-blind trial (51 PedPRM; 44 placebo). Measures included caregiver-reported Sleep and Nap Diary, Composite Sleep Disturbance Index (CSDI), caregiver's Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, and quality of life (WHO-5 Well-Being Index). Results: Ninety-five subjects (74.7% males; mean [standard deviation] age, 9 [4.24]; range, 2-17.5 years) received PedPRM (2/5?mg) according to the double-blind phase dose, for 39 weeks with optional dose adjustment (2, 5, or 10?mg/day) after the first 13 weeks. After 52 weeks of continuous treatment (PedPRM-randomized group) subjects slept (mean [SE]) 62.08 (21.5) minutes longer (p?=?0.007); fell asleep 48.6 (10.2) minutes faster (p?50% decrease; p?=?0.001); and better sleep quality (p?

SUBMITTER: Maras A 

PROVIDER: S-EPMC6306655 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.

Maras Athanasios A   Schroder Carmen M CM   Malow Beth A BA   Findling Robert L RL   Breddy John J   Nir Tali T   Shahmoon Shiri S   Zisapel Nava N   Gringras Paul P  

Journal of child and adolescent psychopharmacology 20181011 10


<b><i>Objective:</i></b> A recent double-blind randomized placebo-controlled study demonstrated 3-month efficacy and safety of a novel pediatric-appropriate prolonged-release melatonin (PedPRM) for insomnia in children and adolescents with autism spectrum disorder (ASD) and neurogenetic disorders (NGD) with/without attention-deficit/hyperactivity disorder comorbidity. Long-term efficacy and safety of PedPRM treatment was studied. <b><i>Methods:</i></b> A prospective, open-label efficacy and safe  ...[more]

Similar Datasets

| S-EPMC6647439 | biostudies-literature
| S-EPMC8084705 | biostudies-literature
| S-EPMC10068748 | biostudies-literature
| S-EPMC6469244 | biostudies-literature
| S-EPMC2933606 | biostudies-literature
2018-02-27 | GSE111176 | GEO
| S-EPMC8900942 | biostudies-literature
| S-EPMC2199264 | biostudies-literature
| S-EPMC7894135 | biostudies-literature
| S-EPMC9829592 | biostudies-literature